February 11, 2020

Moving the Diagnostics Needle for Personalized Care

 

Clinical OMICs featured comments that Eric Schadt, Ph.D., Founder and CEO of Sema4, made in a recent panel discussion titled “Transformative Technologies: Previewing the Value Proposition and Outlook for Disruptive Tools Designed to Enable Personalized Medicine.” The panel was chaired and moderated by Michael Pellini, M.D., a member of Sema4’s Board of Directors. At Sema4, “the focus is on developing actionable data from patients, while also keeping the patient in control of their own health data,” shared Eric. Read the full article here by Chris Anderson, Editor-in-Chief of Clinical OMICs